Nephrology
From the Journals
Type of renal dysfunction affects liver cirrhosis mortality risk
Patients with acute on chronic kidney disease fared the worst.
News
Farxiga gets Fast Track status from FDA
From the Journals
No increase in UTI risk with SGLT-2 inhibitors
compared...
Conference Coverage
Lupus nephritis treatment: Five key components
LAKE BUENA VISTA, FLA. – From antihypertensive therapy to mycophenolate mofetil to steroids, Dr. Michelle Petri lays out her evidence-based take...
Conference Coverage
DECLARE-TIMI58 shows improved kidney function with dapagliflozin
SAN FRANCISCO – The SGLT2 dapagliflozin was better than placebo at slowing down kidney disease in patients with type 2 diabetes
From the Journals
NOACs benefit early stage chronic kidney disease patients
NOACs reduced risk of several adverse events compared with VKAs in a meta-analysis of chronic kidney disease patients.
Latest News
The costs and benefits of SGLT2 inhibitors & GLP-1 RAs
The price tags on these drugs are the biggest barrier to their use.
Feature
Using Obamacare authority, Trump aims to shift dialysis care to patients’ homes
The plan aims to increase the number of patients getting dialysis at home and double the annual number of kidneys available for transplant.
Conference Coverage
VIDEO: Givosiran cuts acute intermittent porphyria attacks in pivotal trial
Despite a modest number of severe adverse effects givosiran seems headed to be the first FDA-approved agent for acute hepatic porphyria.
Latest News
Older women with ESRD face higher mortality, compared with male counterparts
LOS ANGELES – Further investigations regarding sex-based differences in dialysis treatment are required.
Conference Coverage
Blunted cardiac reserve strongly predicts incident hepatorenal syndrome
VIENNA – Cirrhotic patients with end-stage liver disease and a blunted cardiac response to dobutamine had a high...